Oncology Assets Three novel oncology assets at BVD: Ulixertinib (ERK1/2 inhibitor), TEM8-directed ADCs, and Clostridium novyi-NT bacteria. The company pursues early development with a primary emphasis on partnering and out-licensing beyond proof-of-concept, creating licensing opportunities for large or mid-size pharma, investors, or strategic buyers.

Partnership Focus The business model centers on moving assets to proof-of-concept and then partnering or out-licensing. This positions BVD as a ready-to-license partner for organizations seeking de-risked assets and structured collaboration terms such as co-development and milestone-based deals.

Stable Funding A robust, mission-driven funding backbone from the Stowers group provides sustainable capital for ongoing research and clinical work, enabling longer deal horizons and potential for multi-phase funding in collaborations without immediate profitability pressure.

Past Collaboration A translational collaboration with Theralink Technologies signals willingness to engage in external validation and translational science partnerships, suggesting BD candidates could target similar translational partners to bolster asset readiness and speed to clinic.

Ideal Partners Target large and mid-size pharma, biotech venture arms, and asset managers seeking first-in-class or multi-modal oncology programs, including ERK inhibitors, ADCs, and bacteriotherapy, with a preference for early-stage collaborations that can scale with milestones and licensing milestones.